Clinical benefits and cost-effectiveness of 17-year treatment with low-dose interferon-α 2b in a patient with chronic hepatitis C: A case report

Digestive Diseases and Sciences

Volumn 54, Issue 3, 2009, Pages 690-694

  Kawaguchi, Takumi ^a   Sumie, Shuji ^a   Itou, Minoru ^a   Taniguchi, Eitaro ^a   Matoba, Tsunetaka ^b   Sata, Michio ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Shin Koga Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALPHA2B INTERFERON; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CHOLESTEROL;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CASE REPORT; CHOLESTEROL BLOOD LEVEL; COMPUTER ASSISTED TOMOGRAPHY; COST EFFECTIVENESS ANALYSIS; DRUG DOSE REDUCTION; ESOPHAGUS VARICES; FUNDAL HEMORRHAGE; HEALTH CARE COST; HEPATITIS C; HUMAN; INTERSTITIAL PNEUMONIA; LIVER FAILURE; LOW DRUG DOSE; MALE; PRIORITY JOURNAL; PROTHROMBIN TIME; THROMBOCYTE COUNT; TREATMENT DURATION;

ANTIVIRAL AGENTS; COST-BENEFIT ANALYSIS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; LIVER FUNCTION TESTS; MALE; MIDDLE AGED;

EID: 59449105679     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-008-0397-5     Document Type: Article

References (32)

1. S Iino K Hino K Yasuda 1994 Current state of interferon therapy for chronic hepatitis C Intervirology 37 87 100
2. JH Hoofnagle AM di Bisceglie 1997 The treatment of chronic viral hepatitis N Engl J Med 336 347 56 10.1056/NEJM199701303360507
3. H Tilg 1997 New insights into the mechanisms of interferon alfa: an immunoregulatory and anti-inflammatory cytokine Gastroenterology 112 1017 1021 10.1053/gast.1997.v112.pm9041265
4. S Nishiguchi T Kuroki S Nakatani H Morimoto T Takeda S Nakajima 1995 Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis Lancet 346 1051 1055 10.1016/S0140-6736(95)91739-X
5. SW Schalm G Fattovich JT Brouwer 1997 Therapy of hepatitis C: patients with cirrhosis Hepatology 26 128S 132S 10.1002/hep.510260722
6. H Yoshida Y Shiratori M Moriyama Y Arakawa T Ide M Sata 1999 Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT study group. Inhibition of hepatocarcinogenesis by interferon therapy Ann Intern Med 131 174 181
7. M Omata H Yoshida Y Shiratori 2005 Prevention of hepatocellular carcinoma and its recurrence in chronic hepatitis C patients by interferon therapy Clin Gastroenterol Hepatol 3 S141 S143 10.1016/S1542-3565(05)00713-5
8. E Hasegawa M Kobayashi Y Kawamura H Yatsuji H Sezaki T Hosaka 2007 Efficacy and anticarcinogenic activity of interferon for hepatitis C virus-related compensated cirrhosis in patients with genotype 1b low viral load or genotype 2 Hepatol Res 37 793 800 10.1111/j.1872-034X.2007.00140.x
9. M Kudo Y Sakaguchi H Chung K Hatanaka S Hagiwara E Ishikawa 2007 Long-term interferon maintenance therapy improves survival in patients with HCV-related hepatocellular carcinoma after curative radiofrequency ablation. A matched case-control study Oncology 72 Suppl 1 132 138 10.1159/000111719
10. T Berg M von Wagner S Nasser C Sarrazin T Heintges T Gerlach 2006 Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin Gastroenterology 130 1086 1097 10.1053/j.gastro.2006.02.015
11. S Guerret A Desmouliere P Chossegros AM Costa C Badid C Trepo 1999 Long-term administration of interferon-alpha in non-responder patients with chronic hepatitis C: follow-up of liver fibrosis over 5 years J Viral Hepat 6 125 133 10.1046/j.1365-2893.1999.00148.x
12. S Murashima M Tanaka M Haramaki S Yutani Y Nakashima K Harada 2006 A decrease in AFP level related to administration of interferon in patients with chronic hepatitis C and a high level of AFP Dig Dis Sci 51 808 812 10.1007/s10620-006-3211-2
13. H Nomura Y Kashiwagi R Hirano H Tanimoto N Tsutsumi M Higashi 2007 Efficacy of low dose long-term interferon monotherapy in aged patients with chronic hepatitis C genotype 1 and its relation to alpha-fetoprotein: a pilot study Hepatol Res 37 490 497 10.1111/j.1872-034X.2007.00073.x
14. V Mazzaferro R Romito M Schiavo L Mariani T Camerini S Bhoori 2006 Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis Hepatology 44 1543 1554 10.1002/hep.21415
15. K Hayashida I Nagasue T Fukuda A Gunji 2002 The natural history model of hepatitis C virus infection and the economic evaluation of alpha interferon treatment J Epidemiol 12 22 32
16. Y Shiratori N Kato H Yoshida R Nakata M Ihori F Imazeki 2000 Sustained viral response is rarely achieved in patients with high viral load of HCV RNA by excessive interferon therapy Dig Dis Sci 45 565 574 10.1023/A:1005457510354
17. J Shepherd J Jones D Hartwell P Davidson A Price N Waugh 2007 Interferon alpha (pegylated and non-pegylated) and ribavirin for the treatment of mild chronic hepatitis C: a systematic review and economic evaluation Health Technol Assess 11 1 205 iii
18. GL Davis R Esteban-Mur V Rustgi J Hoefs SC Gordon C Trepo 1998 Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International hepatitis interventional therapy group N Engl J Med 339 1493 1499 10.1056/NEJM199811193392102
19. G Dusheiko 1997 Side effects of alpha interferon in chronic hepatitis C Hepatology 26 112S 121S 10.1002/hep.510260720
20. H Itoh H Nakata Y Yokoya S Nakashima T Yamanishi T Hara 1996 Efficacy and side effects of intermittent recombinant interferon-alpha 2a in chronic aggressive hepatitis C: with or without initial daily administration J Gastroenterol Hepatol 11 718 723 10.1111/j.1440-1746.1996.tb00320.x
21. S Nishiguchi S Shiomi S Nakatani T Takeda K Fukuda A Tamori 2001 Prevention of hepatocellular carcinoma in patients with chronic active hepatitis C and cirrhosis Lancet 357 196 197 10.1016/S0140-6736(00)03595-9
22. Y Arase K Ikeda F Suzuki Y Suzuki M Kobayashi N Akuta 2007 Prolonged-interferon therapy reduces hepatocarcinogenesis in aged-patients with chronic hepatitis C J Med Virol 79 1095 102 10.1002/jmv.20866
23. Y Arase K Ikeda A Tsubota F Suzuki Y Suzuki S Saitoh 2004 Interferon therapy for 2 years or longer reduces the incidence of hepatocarcinogenesis in patients with chronic hepatitis C viral infection Intervirology 47 355 361 10.1159/000080880
24. M Gomez-Rubio JC Porres I Castillo JA Quiroga A Moreno V Carreno 1990 Prolonged treatment (18 months) of chronic hepatitis C with recombinant alpha-interferon in comparison with a control group J Hepatol 11 Suppl 1 S63 S67 10.1016/0168-8278(90)90166-O
25. M Yousuf Y Nakano E Tanaka T Sodeyama K Kiyosawa 1992 Persistence of viremia in patients with type-C chronic hepatitis during long-term follow-up Scand J Gastroenterol 27 812 826 10.3109/00365529209011189
26. WG Bennett Y Inoue JR Beck JB Wong SG Pauker GL Davis 1997 Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C Ann Intern Med 127 855 865
27. M Buti MA Casado L Fosbrook JB Wong R Esteban 2000 Cost-effectiveness of combination therapy for naive patients with chronic hepatitis C J Hepatol 33 651 658 10.1034/j.1600-0641.2000.033004651.x
28. M Buti M Medina MA Casado JB Wong L Fosbrook R Esteban 2003 A cost-effectiveness analysis of peginterferon alfa-2b plus ribavirin for the treatment of naive patients with chronic hepatitis C Aliment Pharmacol Ther 17 687 694 10.1046/j.1365-2036.2003.01453.x
29. TR Gildea KM Shermock ME Singer JK Stoller 2003 Cost-effectiveness analysis of augmentation therapy for severe alpha1-antitrypsin deficiency Am J Respir Crit Care Med 167 1387 1392 10.1164/rccm.200209-1035OC
30. H Ishida Y Inoue JB Wong K Okita 2004 Cost-effectiveness of ribavirin plus interferon alpha-2b for either interferon relapsers or non-responders in chronic hepatitis C: a Japanese trial Hepatol Res 28 125 136 10.1016/j.hepres.2003.11.002
31. R San Miguel J Mar JM Cabases F Guillen-Grima M Buti 2003 Cost-effectiveness analysis of therapeutic strategies for patients with chronic hepatitis C previously not responding to interferon Aliment Pharmacol Ther 17 765 773 10.1046/j.1365-2036.2003.01494.x
32. ZM Younossi ME Singer JG McHutchison KM Shermock 1999 Cost effectiveness of interferon alpha2b combined with ribavirin for the treatment of chronic hepatitis C Hepatology 30 1318 1324 10.1002/hep.510300518